Report contents
At a glance
- Business model: Sanofi sells branded prescription drugs and vaccines through Specialty Care, Vaccines and General Medicines, with US payers and national health systems setting net price. Dupixent supplied close to a third of 2024 sales and most growth, but Sanofi splits its profit roughly evenly with Regeneron, so the concentration is in both revenue and economic value.
- Financial quality: Free cash flow stayed between €5.89 billion and €8.48 billion in FY2021–FY2025, and net debt of about €11.2 billion at December 31, 2025 was under 1x EBITDA of €12.48 billion. The caveat is returns: FY2025 ROE was 10.5%, within a 7.3–11.7% range, so cash is dependable but the capital base earns little more than the 8.8% discount rate.
Business model
Business model: one antibody carries the growth story
Three franchises, one payer conversation
Sanofi sells prescription medicines and vaccines. Patients consume them, but insurers, governments and pharmacy benefit managers pay. After the 2025 sale of a 50% controlling stake in its consumer health unit, Opella, to CD&R, the company reports through Specialty Care, Vaccines and General Medicines. That leaves a branded biopharma with a research pipeline attached, not the diversified healthcare conglomerate it was a few years ago. The stage differs by unit: Specialty Care is expanding, Vaccines is mature and moves with public tender calendars, and General Medicines is in managed decline as older products lose exclusivity. Growth now rests on a narrow set of products.
Who actually pays
The United States supplies roughly half of group sales, and there the buyer is a commercial insurer or PBM for most prescriptions, with Medicare Part D and Medicaid covering large segments. List prices are close to fictional: rebates and discounts negotiated plan by plan determine net revenue, and Sanofi does not publish gross-to-net. In Europe and much of the rest of the world, national health systems buy directly, often through tenders, and vaccine purchases run through public bodies such as PAHO and UNICEF. The mix matters because US commercial pricing is where the profit pool sits, while tender markets set volume at thin spreads. A product that wins on volume in a tender market does far less for group earnings than the same volume sold through a US formulary.
The P&L is concentrated in Dupixent
Dupixent, the dupilumab antibody partnered with Regeneron, accounted for close to a third of 2024 sales and most of the group's growth. Its economics are shared: Sanofi books global product sales and then splits profits roughly evenly with Regeneron, so reported revenue overstates what Sanofi keeps relative to a wholly owned drug. US composition-of-matter protection runs to about 2031. Nothing else in the portfolio is close in scale, which makes the 2026–2030 P&L largely a bet on one molecule's label expansions, payer relationships and remaining patent life.
| Franchise | Main products | Who pays | How price is set |
|---|---|---|---|
| Specialty Care | Dupixent, Sarclisa, transplant and MS drugs | US PBMs and insurers, hospital formularies | List price less confidential rebates |
| Vaccines | Influenza, Beyfortus, MenQuadfi, pediatric combinations | National health systems, PAHO/UNICEF, pediatricians | Tender bids, seasonal campaigns |
| General Medicines | Insulin, legacy cardiovascular drugs | Payers and tenders; cash pay in emerging markets | Generic-referenced, little pricing power |
Beyfortus, the RSV antibody for infants co-developed with AstraZeneca, is the clearest example of how differently the vaccine channel behaves. It sells to ministries and procurement agencies that decide annually whether to fund a birth-cohort program, so a single advisory recommendation can move a season's revenue. That is a buyers' market in a way Dupixent's US dermatology and asthma business is not.
Bargaining power is not uniform
In specialty care Sanofi has real leverage over US payers: Dupixent treats large chronic populations with few close substitutes, and switching means re-authorization and new injection training. The leverage is bounded by rebate competition and by oral and injectable rivals entering the same inflammatory pathways. Vaccines carry high manufacturing barriers, particularly for strain-matched influenza, but the customer is a government with a budget cycle. General Medicines has no leverage at all; price follows generic entry.
The refill problem
Sanofi's late-stage list, including amlitelimab, tolebrutinib, frexalimab and rilzabrutinib (marketed as Wayrilz for immune thrombocytopenia), is credible but unproven at Dupixent scale. Each is a specialist product that might reach €1–2 billion; the group needs one to reach several times that. Business development can close the gap, though the price paid decides whether a deal adds value, and a strong balance sheet makes overpaying easier. Sanofi also does not split sales growth into price and volume, and it does not disclose Dupixent margins after the Regeneron profit share. Both gaps make it hard to tell whether growth comes from more patients or higher net prices.
The judgment would change if a second asset clears Phase 3 with clean data in a large immunology or neurology population, or if Dupixent erosion after 2031 proves slower than the patent date implies because of device, formulation or pediatric exclusivity. A faster loss of US formulary position would shrink the cash that funds the pipeline in the first place.
Questions worth following
- Can Dupixent hold its US formulary position as rebates rise?
Formulary access, not clinical preference, sets US volume for Dupixent. If payers extract deeper rebates or add step therapy, pricing power is weaker than sales growth implies, and the profit pool funding the rest of Sanofi's pipeline shrinks.
- Will any Sanofi pipeline drug reach Dupixent scale by 2030?
Dupixent funds the group and faces US exclusivity around 2031. Whether amlitelimab, tolebrutinib, frexalimab or another asset reaches several billion euros of sales decides if Sanofi grows through that transition or shrinks into it, and whether deal-making is a choice or a necessity.
- Can Sanofi win repeat national contracts for Beyfortus?
Vaccines revenue depends on government buyers awarding multi-season contracts. Repeat Beyfortus awards would show the RSV antibody has become a standing infant immunization program; one-off campaigns would leave the unit exposed to tender timing and to price competition from rivals.
Financial quality
Financial quality: cash conversion outruns returns
Sanofi converts profit into cash reliably, borrows modestly, and has not posted a negative free cash flow year since at least FY2021. The weak link is the return on the capital tied up in the business. ROE has ranged between 7.3% and 11.7% across the last five fiscal years, and the FY2025 figure of 10.5% rests on net income that ran ahead of operating profit. Dependable cash, unremarkable returns: that is what the record supports.
| Metric (EUR bn unless noted) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Q3 2026 | Assessment |
|---|---|---|---|---|---|---|---|
| Revenue | 39.17 | 40.56 | 41.62 | 44.29 | 46.72 | 15.23 | Steady, 4.5% four-year CAGR |
| Gross margin (%) | 68.7 | 70.7 | 69.7 | 70.2 | 72.1 | 76.2 | Strong |
| Operating income | 8.13 | 10.16 | 6.96 | 7.25 | 9.60 | 4.71 | Adequate |
| EBIT | 8.19 | 10.40 | 6.96 | 7.45 | 6.80 | 4.43 | Adequate |
| Net income | 6.22 | 8.37 | 5.40 | 5.56 | 7.81 | 3.02 | Adequate |
| Net margin (%) | 15.9 | 20.6 | 13.0 | 12.6 | 16.7 | 19.8 | Adequate |
| ROE (%) | 9.4 | 11.7 | 7.3 | 7.3 | 10.5 | 4.3 | Adequate |
| Liabilities/assets (%) | 42.6 | 40.7 | 41.2 | 41.4 | 43.4 | 43.8 | Adequate |
| Current ratio | 1.44 | 1.42 | 1.27 | 1.46 | 1.09 | 1.12 | Thin |
| Interest expense | 0.38 | 0.39 | 0.51 | 0.62 | 0.63 | 0.22 | Strong coverage |
| Receivable turns (x) | 4.0 | 4.0 | 3.8 | 4.1 | 4.3 | 3.2 | Adequate, ~85 days |
| Inventory turns (x) | 1.4 | 1.3 | 1.4 | 1.4 | 1.3 | Not disclosed | Adequate |
| Operating cash flow | 10.52 | 10.53 | 10.26 | 9.08 | 10.75 | 3.87 | Strong |
| Capex, implied | 2.04 | 2.21 | 2.91 | 3.19 | 3.54 | 0.63 | 5–8% of revenue |
| Free cash flow | 8.48 | 8.32 | 7.35 | 5.89 | 7.21 | 3.24 | Strong |
| FCF/net income (x) | 1.36 | 0.99 | 1.36 | 1.06 | 0.92 | 1.07 | Strong |
| OCF/net income (x) | 1.69 | 1.26 | 1.90 | 1.63 | 1.38 | 1.28 | Exceptional |
*Single quarter to September 30, 2026; flow items are not comparable with the annual columns. Capex is derived as operating cash flow less free cash flow. The liabilities/assets series above is calculated from reported balance-sheet totals; the alternative ratio series supplied with the data (13–17%) does not reconcile with liabilities of €55.1 billion on €126.8 billion of assets, so it is not used.
Gross margin is improving; operating leverage is not
Third-quarter 2026 revenue of €15.23 billion rose 15.6% year over year and the gross margin reached 76.2%, up from 72.1% for FY2025 and 68.7% in FY2021. Mix and pricing are moving the right way. The gain has not reached the operating line: over the first nine months of 2026, revenue rose 12.3% to €38.77 billion while EBIT rose 1.4% to €7.73 billion, so the EBIT margin fell roughly 2.2 percentage points to 19.9% even as the gross margin added 1.7 points. Selling, research and launch spending is absorbing the benefit. Because equity stood at €72.9 billion on September 30, 2026, with about €42 billion of goodwill at the June quarter, a 70%-plus gross margin still produces a mid-single-digit return on the capital base.
Cash conversion is the genuine strength
Capex has run at 5.2% to 7.6% of revenue, so most operating cash falls through to free cash flow, which stayed between €5.89 billion and €8.48 billion every year from FY2021 to FY2025, with FCF/net income at or above 0.92 throughout. Financing outflows of €5.8–8.2 billion a year, covering dividends and repurchases, have been roughly matched by that free cash flow. Net debt of about €11.2 billion at December 31, 2025 is under 1x EBITDA of €12.48 billion, and interest expense of €0.63 billion is covered more than ten times by EBIT. Solvency is not the constraint.
One caution on the conversion ratios: FY2025's 1.38x OCF/net income is partly arithmetic. Net income carried charges that cash flow did not, so the ratio overstates collection quality. The durable evidence is the five-year free cash flow record and low capital intensity, not any single year's ratio.
Reported earnings carry a large non-operating component
The quarterly pattern is unusually wide. In Q2 2025 net income was €3.94 billion against EBIT of €1.51 billion and EBITDA of €3.27 billion; net income exceeded EBITDA, which requires substantial income booked below the operating line. In Q4 2025 an operating loss of €1.04 billion sat beside positive EBIT of €1.85 billion. For the full year, operating income of €9.60 billion exceeded EBIT of €6.80 billion. The practical result: nine-month 2026 net income of €4.97 billion is 42% below the €8.61 billion reported a year earlier even though revenue grew 12.3%. That comparison describes last year's one-offs more than anything that changed in 2026.
Where the numbers need checking
- Composition of FY2025 earnings. The gap between operating income and EBIT, and between EBIT and net income, needs the underlying line items. Until the annual report's other operating and non-operating lines are read together, the recurring earnings base is an estimate.
- Working-capital lines that do not reconcile. Inventory appears as €10.21 billion at December 31, 2025 but €24.5 billion at September 30, 2025 and €25.02 billion a year later; receivables swing between €0.33 billion and €11.05 billion; goodwill moves from €69.09 billion in Q1 2026 to €41.95 billion in Q2 2026. These cannot all be right. If the €25 billion inventory figure is genuine, roughly €15 billion of stock sits on the balance sheet and a current ratio of 1.12 with a quick ratio of 0.27 points to a working-capital build that would weigh on 2026 cash flow.
- Goodwill against returns. About €42 billion of goodwill is a third of assets while ROE sits near 10%. Impairment testing rests on long-run sales projections, so a large patent loss or a failed late-stage program would put both book equity and the return base under pressure.
Questions worth following
- Can Sanofi earn its cost of capital on €42 billion of goodwill?
Returns sit below the 12–20% band that would normally justify acquisition-heavy balance sheets, and goodwill is roughly a third of assets. Whether the acquired base earns an adequate return decides if reinvestment creates value or merely adds scale.
- Can Sanofi grow net income without non-operating gains?
FY2025 net income of €7.81 billion exceeded EBIT of €6.80 billion, and one quarter's net income topped EBITDA. If headline earnings depend on items below the operating line, the reported growth rate misstates the underlying business and skews any comparison of margins or returns.
- Can Sanofi fund its dividend and buybacks from free cash flow?
Financing outflows of €8.21 billion in FY2025 against free cash flow of €7.21 billion left a small gap. Whether that gap persists or widens determines if shareholder returns keep coming from operations or start drawing on the balance sheet.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Key risksWhat could break the investment case
- Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
- SummaryOur overall judgement and what to watch next
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Sanofi ADR
Sanofi ADR
Business, moat and key questions
Open company page